• by Bruce Carlson
  • December 10 2018


Smartphones and IVD: Early, But Getting There

Smartphones and IVD: Early, But Getting There

Development-stage projects - and a few products- mark the current field of smartphone in-vitro combinations, per Kalorama's new report.

  • by Aaron Hackle
  • December 6 2018


#BIOMEDevice2018: Kalorama Presents IVD Findings, Sums Up Best Opportunities in Testing, Biosensors and AI Discussed

#BIOMEDevice2018:  Kalorama Presents IVD Findings, Sums Up Best Opportunities in Testing, Biosensors and AI Discussed

At BIOMEDevice San Jose, leading device, testing, accessories and contract manufacturing firms presented their latest technology. Kalorama Information was there and presented the IVD market picture from its latest Worldwide Market for In Vitro Diagnostic Test report. Firms with new MI surgery, biosensor technologies and other products exhibited.

  • by Bruce Carlson
  • December 4 2018


Where Clinical Sequencing Is Now

Where Clinical Sequencing Is Now

Do NGS tests really offer useful insights beyond routine testing for targeted mutations? Are the high costs justified? Should everyone be sequenced? And what will happen when the price drops seriously? We discuss these topics in this article.